Azitra, Inc. has been notified by NYSE American that it has resolved continued listing deficiencies under Sections 1003(a)(ii) and 1003(a)(iii) and will no longer carry the '.BC' indicator. The company maintains a focus on its clinical development pipeline and adherence to listing requirements.